Deregulation in cancer often leads to constitutive overexpression of MYC genes, achieved through gross genetic abnormalities, including gene amplification; chromosomal translocations; increased enhancer activity, mainly through a mechanism of enhancer hijacking; and aberrant signal transduction leading to increased c-MYC/MYCN transcription or increased mRNA and protein stability [176,177,178]. The gene discussed is MYCN; the disease is cancer.